Intercept Pharmaceuticals (NASDAQ: ICPT)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Intercept Pharmaceuticals Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intercept Pharmaceuticals Company Info
Intercept Pharmaceuticals, Inc.
News & Analysis
Investors are cheering the drugmaker's Q3 update.
Poor earnings and a business setback were costly for these companies.
The biotech can't seem to catch a break.
Reddit's retail investors may soon be swooning over this under-the-radar trio of heavily short-sold companies.
The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?
The company's quarterly results were fine, but the more important news from the biopharmaceutical wasn't financial.
The company's share price is down more than 60% for the year, but could positive news on its new nonalcoholic steatohepatitis (NASH) drug make an investor a millionaire?
A better-than-expected quarter helps ease the pain of a recent FDA denial.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/05/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ICPT earnings call for the period ending September 30, 2021.
ICPT earnings call for the period ending June 30, 2021.
ICPT earnings call for the period ending March 31, 2021.
ICPT earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.